- Home
- INTS vs MDAI Comparison
INTS vs MDAI Comparison
Compare INTS & MDAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- INTS
- MDAI
- Stock Information
- Founded
- INTS 2012
- MDAI 2013
- Country
- INTS United States
- MDAI United States
- Employees
- INTS N/A
- MDAI N/A
- Industry
- INTS Biotechnology: Pharmaceutical Preparations
- MDAI Medical/Dental Instruments
- Sector
- INTS Health Care
- MDAI Health Care
- Exchange
- INTS Nasdaq
- MDAI Nasdaq
- Market Cap
- INTS 30.8M
- MDAI 33.1M
- IPO Year
- INTS 2023
- MDAI N/A
- Fundamental
- Price
- INTS $0.54
- MDAI $1.24
- Analyst Decision
- INTS Strong Buy
- MDAI Strong Buy
- Analyst Count
- INTS 3
- MDAI 2
- Target Price
- INTS $8.50
- MDAI $4.75
- AVG Volume (30 Days)
- INTS 362.2K
- MDAI 142.8K
- Earning Date
- INTS 05-20-2025
- MDAI 05-13-2025
- Dividend Yield
- INTS N/A
- MDAI N/A
- EPS Growth
- INTS N/A
- MDAI N/A
- EPS
- INTS N/A
- MDAI N/A
- Revenue
- INTS N/A
- MDAI $29,581,000.00
- Revenue This Year
- INTS N/A
- MDAI N/A
- Revenue Next Year
- INTS N/A
- MDAI $102.58
- P/E Ratio
- INTS N/A
- MDAI N/A
- Revenue Growth
- INTS N/A
- MDAI 63.83
- 52 Week Low
- INTS $0.50
- MDAI $0.82
- 52 Week High
- INTS $5.28
- MDAI $3.25
- Technical
- Relative Strength Index (RSI)
- INTS 18.34
- MDAI 46.29
- Support Level
- INTS $0.55
- MDAI $1.25
- Resistance Level
- INTS $0.59
- MDAI $1.32
- Average True Range (ATR)
- INTS 0.12
- MDAI 0.06
- MACD
- INTS -0.02
- MDAI 0.01
- Stochastic Oscillator
- INTS 4.71
- MDAI 52.38
About INTS Intensity Therapeutics Inc. Common stock
Intensity Therapeutics Inc is a clinical-stage biotechnology company pioneering a new immune-based approach to treat solid tumor cancers. The company leverages its DfuseRxtechnology platform to create new, proprietary drug formulations that, following direct injection, rapidly disperse throughout a tumor and diffuse therapeutic agents into cancer cells. Intensity's product candidates have the potential to induce an adaptive systemic immune response that not only attacks the injected tumor, but also non-injected tumors. Their pipeline is focused on realizing the full potential of INT230-6 in metastatic and local disease settings to help cancer patients with unmet medical need.
About MDAI Spectral AI Inc.
Spectral AI Inc is an AI company, focused on predictive medical diagnostics. Spectral is devoting substantially all of its efforts towards the research and development of its DeepView System, an internally developed MSI device that has designated FDA BDD status. Its DeepView System uses proprietary algorithms to distinguish between damaged and healthy human tissue invisible to the naked eye, providing Day One healing assessments in seconds. The Company's output is specifically engineered to allow the physician to make a more accurate, timely, and informed decision regarding the treatment of the patient's wound.